Cue Biopharma's CUE-221 clears Phase 2 test in chronic spontaneous urticaria

Cue Biopharma has reported positive topline data from a Phase 2 clinical study of CUE-221 in patients with chronic spontaneous urticaria, a condition marked by recurring hives and swelling without an identifiable trigger.

The company said the trial met its primary endpoint as well as key secondary endpoints. It did not disclose further details on the magnitude of the treatment effect or the specific measures used in the analysis.

Topline results typically represent the first look at a study's main findings before a fuller dataset is released. The outcome is a milestone for the programme, which now moves forward on the strength of the mid-stage readout.

Chronic spontaneous urticaria is a persistent form of urticaria that can significantly affect quality of life, and treatment options remain limited for patients who do not respond to standard antihistamines. Companies developing new therapies in this space are watched closely by clinicians and investors alike.

Cue Biopharma has not indicated when it expects to present the complete Phase 2 dataset or what regulatory steps may follow. Further company coverage is expected.